

# Tracy J Ruckwardt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2398076/publications.pdf>

Version: 2024-02-01

19  
papers

3,132  
citations

623574

14  
h-index

794469

19  
g-index

22  
all docs

22  
docs citations

22  
times ranked

6276  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	13.7	1,153
2	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
3	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019, 365, 505-509.	6.0	207
4	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
5	Immunological Lessons from Respiratory Syncytial Virus Vaccine Development. <i>Immunity</i> , 2019, 51, 429-442.	6.6	99
6	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
7	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020, 33, 108322.	2.9	59
8	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. <i>Immunity</i> , 2021, 54, 1869-1882.e6.	6.6	59
9	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020, 6, eaba5068.	4.7	50
10	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1111-1120.	5.2	38
11	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021, 54, 769-780.e6.	6.6	37
12	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30
13	Epitope-Specific Serological Assays for RSV: Conformation Matters. <i>Vaccines</i> , 2019, 7, 23.	2.1	26
14	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 772864.	2.2	21
15	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
16	Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. <i>The Lancet Healthy Longevity</i> , 2022, 3, e405-e416.	2.0	9
17	Level of maternal respiratory syncytial virus (RSV) F antibodies in hospitalized children and correlates of protection. <i>International Journal of Infectious Diseases</i> , 2021, 109, 56-62.	1.5	7
18	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	7

#	ARTICLE	IF	CITATIONS
19	Recurrent respiratory syncytial virus infection in a CD14 deficient patient. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	5